The ratio of matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Vogel, Lotte K ^a   Sæbø, Mona ^b   Skjelbred, Camilla F ^b,c   Abell, Kathrine ^a   Pedersen, Esben D K ^a   Vogel, Ulla ^d   Kure, Elin H ^b,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^c TELEMARK HOSPITAL   (Norway)

^d NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; INHIBITOR PROTEIN; MATRIPTASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; DYSPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION;

ADENOMA; CARCINOMA; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 33746604484     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-176     Document Type: Article

References (34)

1. Kim MG, Chen C, Lyu MS, Cho EG, Park D, Kozak C, Schwartz RH: Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 1999, 49:420-428.
2. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB: Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999, 274:18231-18236.
3. Takeuchi T, Shuman MA, Craik CS: Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A 1999, 96:11054-11061.
4. Tanimoto H, Underwood LJ, Wang YX, Shigemasa K, Parmley TH, O'Brien TJ: Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumor Biology 2001, 22:104-114.
5. Velasco G, Cal S, Quesada V, Sanchez LM, Lopez-Otin C: Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002, 277:37637-37646.
6. Hooper JD, Campagnolo L, Goodarzi G, Truong TN, Stuhlmann H, Quigley JP: Mouse matriptase-2: identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem J 2003, 373:689-702.
7. Szabo R, Netzel-Arnett S, Hobson JP, Antalis TM, Bugge TH: Matriptase-3 is a novel, evolutionarily conserved matriptase/MT-SP1 homologue that encodes a functional type II transmembrane serine protease with conserved expression in mice and humans. Thrombosis and Haemostasis 2005, 93:A17-A17.
8. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000, 275:26333-26342.
9. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH: Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002, 21:3765-3779.
10. List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY, Bugge TH: Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 2003, 163:901-910.
11. Benaud C, Oberst M, Hobson JP, Spiegel S, Dickson RB, Lin CY: Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem 2002, 277:10539-10546.
12. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY: Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001, 158:1301-1311.
13. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al Nafussi A, Smyth JF, Gabra H, Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002, 8:1101-1107.
14. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DI, Camp RL: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003, 63:1101-1105.
15. Shimomura T, Denda K. Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N: Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997, 272:6370-6376.
16. Tanaka H, Nagaike K, Takeda N, Itoh H, Kohama K, Fukushima T, Miyata S, Uchiyama S, Uchinokura S, Shimomura T, Miyazawa K, Kitamura N, Yamada G, Kataoka H: Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta. Molecular and Cellular Biology 2005, 25:5687-5698.
17. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind SJ, Bugge TH: Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes & Development 2005, 19:1934-1950.
18. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA: Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004, 125:1843-1852.
19. Santin AD, Zhan FH, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian EM, Cannon MJ, Shaughnessy J, Pecorelli S: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal of Cancer 2004, 112:14-25.
20. Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98:1898-1904.
21. Riddick ACP, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer 2005, 92:2171-2180.
22. Lee JW, Yong SS, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB, Bae DS: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 2005, 36:626-633.
23. Parr C, Watkins G, Mansel RE, Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004, 10:202-211.
24. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study. Scandinavian Journal of Gastroenterology 2003, 38:635-642.
25. [http://www.clinicaltrials.gov/]:. 2006.
26. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G: The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003, 38:635-642.
27. Johnson MR, Wang KS, Smith JB, Heslin MJ, Diasio RB: Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry 2000, 278:175-184.
28. Norway TCR: Cancer in Norway 2001 Oslo, InfoPrint as; 2004.
29. Johnson MD, Oberst MD, Lin CY, Dickson RB: Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2003, 3:331-338.
30. Zeng L, Cao J, Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World Journal of Gastroenterology 2005, 11:6202-6207.
31. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y: Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and downregulated in renal cell carcinoma. Journal of Urology 2004, 171:890-896.
32. Lee SL, Dickson RB, Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. Journal of Biological Chemistry 2000, 275:36720-36725.
33. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB: CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004, 61:228-235.
34. Nagaike K, Kohama K, Uchiyama S, Tanaka H, Chijiiwa K, Itoh H, Kataoka H: Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Science 2004, 95:728-735.